1 |
|
Interactions between inflammation and lipid metabolism: Relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis
Dyslipidemia and inflammation are well known causal risk factors the development of atherosclerosis. The interplay between lipid metabolism and inflammation at multiple levels in metabolic active tissues may exacerbate the development of atherosclerosis, and will be discussed in this review. Cholesterol, fatty acids and modified lipids can directly activate inflammatory pathways. In addition, circulating (modified) lipoproteins modulate the activity of leukocytes. Vice versa, proinflammatory signaling (i.e. cytokines) in pre-clinical models directly affects lipid metabolism. Whereas the main lipid-lowering drugs all have potent anti-inflammatory actions, the lipid-modulating actions of anti-inflammatory agents appear to be less straightforward. The latter have mainly been evaluated in pre-clinical models and in patients with chronic inflammatory diseases, which will be discussed. The clinical trials that are currently conducted to evaluate the efficacy of anti-inflammatory agents in the treatment of cardiovascular diseases may additionally reveal potential (beneficial) effects of these therapeutics on lipid metabolism in the general population at risk for CVD. © 2013 Elsevier Ireland Ltd.
|
[Abstract]
|
2 |
|
Aspirin reduces hypertriglyceridemia by lowering VLDL-triglyceride production in mice fed a high-fat diet
Systemic inflammation is strongly involved in the pathophysiology of the metabolic syndrome, a cluster of metabolic risk factors that includes hypertriglyceridemia. Aspirin treatment lowers inflammation via inhibition of NF-?B activity but also reduces hypertriglyceridemia in humans. The aim of this study was to investigate the mechanism by which aspirin improves hypertriglyceridemia. Human apolipoprotein CI (apoCI)-expressing mice (APOC1 mice), an animal model with elevated plasma triglyceride (TG) levels, as well as normolipidemic wild-type (WT) mice were fed a high-fat diet (HFD) and treated with aspirin. Aspirin treatment reduced hepatic NF-?B activity in HFD-fed APOC1 and WT mice, and in addition, aspirin decreased plasma TG levels (-32%, P < 0.05) in hypertriglyceridemic APOC1 mice. This TG-lowering effect could not be explained by enhanced VLDL-TG clearance, but aspirin selectively reduced hepatic production of VLDL-TG in both APOC1 (-28%, P < 0.05) and WT mice (-33%, P < 0.05) without affecting VLDL-apoB production. Aspirin did not alter hepatic expression of genes involved in FA oxidation, lipogenesis, and VLDL production but decreased the incorporation of plasma-derived FA by the liver into VLDL-TG (-24%, P < 0.05), which was independent of hepatic expression of genes involved in FA uptake and transport. We conclude that aspirin improves hypertriglyceridemia by decreasing VLDL-TG production without affecting VLDL particle production. Therefore, the inhibition of inflammatory pathways by aspirin could be an interesting target for the treatment of hypertriglyceridemia. © 2011 the American Physiological Society.
|
[Abstract]
|
3 |
|
CD36 is important for adipocyte recruitment and affects lipolysis
article |
2013
|
Author: |
Vroegrijk, I.O.
·
Klinken, J.B. van
·
Diepen, J.A. van
·
Berg, S.A. van den
·
Febbraio, M.
·
Steinbusch, L.K.
·
Glatz, J.F.
·
Havekes, L.M.
·
Voshol, P.J.
·
Rensen, P.C.
·
Dijk, K.W. van
·
Harmelen, V. van
|
Keywords: |
Health · Food and Nutrition · Healthy Living · Life · MHR - Metabolic Health Research · EELS - Earth, Environmental and Life Sciences
|
Objective: The scavenger receptor CD36 facilitates the cellular uptake of long-chain fatty acids. As CD36-deficiency attenuates the development of high fat diet (HFD)-induced obesity, the role of CD36-deficiency in preadipocyte recruitment and adipocyte function was set out to characterize. Design and methods: Fat cell size and number were determined in gonadal, visceral, and subcutaneous adipose tissue of CD36(-/-) and WT mice after 6 weeks on HFD. Basal lipolysis and insulin-inhibited lipolysis were investigated in gonadal adipose tissue. Results: CD36(-/-) mice showed a reduction in adipocyte size in all fat pads. Gonadal adipose tissue also showed a lower total number of adipocytes because of a lower number of very small adipocytes (diameter <50 μm). This was accompanied by an increased pool of preadipocytes, which suggests that CD36-deficiency reduces the capacity of preadipocytes to become adipocytes. Regarding lipolysis, in adipose tissue from CD36(-/-) mice, cAMP levels were increased and both basal and 8-bromo-cAMP stimulated lipolysis were higher. However, insulin-mediated inhibition of lipolysis was more potent in CD36(-/-) mice. Conclusions: These results indicate that during fat depot expansion, CD36-deficiency negatively affects preadipocyte recruitment and that in mature adipocytes, CD36-deficiency is associated with increased basal lipolysis and insulin responsiveness.
|
[PDF]
[Abstract]
|
4 |
|
META060 protects against diet-induced obesity and insulin resistance in a high-fat–diet fed mouse
article |
2012
|
Author: |
Vroegrijk, I.O.C.M.
·
Diepen, J.A. van
·
Berg, S.A. van den
·
Romijn, J.A.
·
Havekes, L.M.
·
Dijk, K.W. van
·
Darland, G.
·
Konda, V.
·
Tripp, M.L.
·
Bland, J.S.
·
Voshol, P.J.
|
Keywords: |
Nutrition · Glucose · Insulin · META060 · Metabolism · Mouse · Obesity · Hops · Food and Nutrition · Healthy Living · Life · MHR - Metabolic Health Research · EELS - Earth, Environmental and Life Sciences
|
Objective: We investigated whether a reduced iso-α acid derived from an extract of Humulus lupulus L., META060, had an effect on weight gain, body composition, and metabolism in a high-fat–diet (HFD) fed mouse model. Methods: Weight gain was monitored for up to 20 wk in mice receiving a low-fat diet, an HFD, or an HFD supplemented with META060 or rosiglitazone. Body composition was determined using dual-energy x-ray absorptiometric analysis. Indirect calorimetric measurements were performed to investigate the energy balance in the mice, and oral glucose tolerance tests were administered to examine the effect of META060 on the glycemic response. Results: The HFD-fed mice administered META060 for 14 wk had a significantly lower mean weight than HFD-fed mice (30.58 ± 0.5 versus 37.88 ± 0.7 g, P < 0.05). Indirect calorimetric measurements showed an increased metabolic flexibility in mice supplemented with META060. In addition, glucose tolerance was improved, comparable to the effects of rosiglitazone treatment. Conclusions: META060 has potential therapeutic value for managing obesity and insulin resistance, and further research into the mechanism of action is warranted.
|
[PDF]
[Abstract]
|
5 |
|
Hepatocyte-specific IKKβ expression aggravates atherosclerosis development in APOE*3-Leiden mice
article |
2012
|
Author: |
Wong, M.C.
·
Diepen, J.A. van
·
Hu, L.
·
Guigas, B.
·
Boer, H.C. de
·
Puijvelde, G.H. van
·
Kuiper, J.
·
Zonneveld, A.J. van
·
Shoelson, S.E.
·
Voshol, P.J.
·
Romijn, J.A.
·
Havekes, L.M.
·
Tamsma, J.T.
·
Rensen, P.C.N.
·
Hiemstra, P.S.
·
Berbée, J.F.P.
|
Keywords: |
Biology · Atherosclerosis · Hepatocyte · Inflammation · Lipid metabolism · Liver · Mouse models · NF-κB · Healthy Living · Life · MHR - Metabolic Health Research · EELS - Earth, Environmental and Life Sciences
|
Objective: The liver is the key organ involved in systemic inflammation, but the relation between hepatic inflammation and atherogenesis is poorly understood. Since nuclear factor-κB (NF-κB) is a central regulator of inflammatory processes, we hypothesized that chronically enhanced hepatic NF-κB activation, through hepatocyte-specific expression of IκB kinase-β (IKKβ) (LIKK), will aggravate atherosclerosis development in APOE*3-Leiden (E3L) mice. Methods and results: E3L.LIKK and E3L control littermates were fed a Western-type diet for 24 weeks. E3L.LIKK mice showed a 2.3-fold increased atherosclerotic lesion area and more advanced atherosclerosis in the aortic root with less segments without atherosclerotic lesions (11% vs. 42%), and more segments with mild (63% vs. 44%) and severe (26% vs. 14%) lesions. Expression of LIKK did not affect basal levels of inflammatory parameters, but plasma cytokine levels tended to be higher in E3L.LIKK mice after lipopolysaccharide (LPS) administration. E3L.LIKK mice showed transiently increased plasma cholesterol levels, confined to (V)LDL. This transient character resulted in a mild (+17%) increased cumulative plasma cholesterol exposure. Conclusion: We conclude that selective activation of NF-κB in hepatocytes considerably promotes atherosclerosis development which is (at least partly) explained by an increased sensitivity to proinflammatory triggers and transiently increased plasma cholesterol levels. © 2011 Elsevier Ireland Ltd.
|
[Abstract]
|
6 |
|
Caspase-1 deficiency in mice reduces intestinal triglyceride absorption and hepatic triglyceride secretion
article |
2013
|
Author: |
Diepen, J.A. van
·
Stienstra, R.
·
Vroegrijk, I.O.C.M.
·
Berg, S.A.A. van den
·
Salvatori, D.
·
Hooiveld, G.J.
·
Kersten, S.
·
Tack, C.J.
·
Netea, M.G.
·
Smit, J.W.A.
·
Joosten, L.A.B.
·
Havekes, L.M.
·
Dijk, K.W. van
·
Rensen, P.C.N.
|
Keywords: |
Health · Absorption · Caspase-1 · Chylomicron · Intestine · Lipid · Liver · Metabolism · Triglyceride · VLDL · Healthy for Life · Healthy Living · Life · MHR - Metabolic Health Research · EELS - Earth, Environmental and Life Sciences
|
Caspase-1 is known to activate the proinflammatory cytokines IL-1β and IL-18. Additionally, it can cleave other substrates, including proteins involved in metabolism. Recently, we showed that caspase-1 deficiency in mice strongly reduces high-fat diet-induced weight gain, at least partly caused by an increased energy production. Increased feces secretion by caspase-1-deficient mice suggests that lipid malabsorption possibly further reduces adipose tissue mass. In this study we investigated whether caspase-1 plays a role in triglyceride-(TG)-rich lipoprotein metabolism using caspase-1-deficient and wild-type mice. Caspase-1 deficiency reduced the postprandial TG response to an oral lipid load, whereas TG-derived fatty acid (FA) uptake by peripheral tissues was not affected, demonstrated by unaltered kinetics of [3H]TG- labeled very low-density lipoprotein (VLDL)-like emulsion particles. An oral gavage of [3H]TG-containing olive oil revealed that caspase-1 deficiency reduced TG absorption and subsequent uptake of TG-derived FA in liver, muscle, and adipose tissue. Similarly, despite an elevated hepatic TG content, caspase-1 deficiency reduced hepatic VLDL-TG production. Intestinal and hepatic gene expression analysis revealed that caspase-1 deficiency did not affect FA oxidation or FA uptake but rather reduced intracellular FA transport, thereby limiting lipid availability for the assembly and secretion of TG-rich lipoproteins. The current study reveals a novel function for caspase-1, or caspase-1-cleaved substrates, in controlling intestinal TG absorption and hepatic TG secretion. Copyright © 2013 by the American Society for Biochemistry and Molecular Biology, Inc.
|
[PDF]
[Abstract]
|